Drug intelligence / Profile preview

BioCart

Development stage: Unknown
Lead developer: Histogenics
Modality: Cell Therapies
Administration: Intraarticular

Overview

BioCart is a product developed by Histogenics, a company specializing in tissue regeneration and chondrocyte cell therapeutics. It was subject to a license agreement with AT Grade for distribution in Italy, likely for applications related to cartilage repair. The distribution agreement for BioCart was terminated in March 2012, as it was no longer considered part of Histogenics' strategic programs.

Brand names: BioCart

Beyond the preview

Go deeper on BioCart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioCart.

Explore the full profile